Prospective study on clinical efficacy of Zofigo on castration resistant prostate cancer with bone metastasis

Prospective study on clinical efficacy of Zofigo on castration resistant prostate cancer with bone metastasis - Effect of Zofigo on castration resistant prostate cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024054

Enrollment

Registered

2016-09-14

Start date

2016-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: castration resistant prostate cancer bone metastasis match to criteria for zofigo treatment obtain written informed consent

Exclusion criteria

Exclusion criteria: inflammatory bowel disease spinal cord compression due to bone metastasis without optimal treatment unfixed fracture other reasons considered for unfit to Zofigo treatment

Design outcomes

Primary

Measure	Time frame
Change rates of alkaline phosphatase levelsat 12 weeks after the initiation treatment	—

Countries

Japan

Contacts

Public ContactYoshiyuki Miyazawa

Gunma University Graduate School of Medicine Department of Urology

miya.yoshi@hotmail.com027-220-8303

Outcome results